Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study

被引：91
|
作者：
Qin, Shukui
Chen, Zhendong
Fang, Weijia
Ren, Zhenggang
Xu, Ruocai
Ryoo, Baek-Yeol
Meng, Zhiqiang
Bai, Yuxian
Chen, Xiaoming
Liu, Xiufeng
Xiao, Juxiang
Ho, Gwo Fuang
Mao, Yimin
Ye, Xing
Ying, Jieer
Li, Jianfeng
Zhong, Wen Yan
Zhou, Yu
Siegel, Abby B.
Hao, Chunyi
机构：
[1] Nanjing Chinese Med Univ, Jinling Hosp, Ctr Canc, Nanjing, Peoples R China
[2] Anhui Med Univ, Hosp 2, Hefei, Peoples R China
[3] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[5] Hunan Canc Hosp, Changsha, Peoples R China
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[7] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[8] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[9] Guangdong Prov Peoples Hosp, Dept Intervent Radiol, Guangzhou, Peoples R China
[10] Chinese PLA, Eastern Theater Gen Hosp, Nanjing, Peoples R China
[11] Xi An Jiao Tong Univ, Affiliated Hosp 1, Shaaxi, Peoples R China
[12] Univ Malaya, Dept Clin Oncol, Fac Med, Kuala Lumpur, Malaysia
[13] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai, Peoples R China
[14] Deyang Hosp, Deyang, Peoples R China
[15] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Inst Canc & Basic Med IBMC, Hangzhou, Zhejiang, Peoples R China
[16] MSD China, Beijing, Peoples R China
[17] MSD China, Shanghai, Peoples R China
[18] Columbia Univ, New York, NY USA
[19] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
383
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase II study of geftinib versus best supportive care as second or third line therapy in advanced squamous cell carcinoma of lung in Asian Indians
    Kumar, N.
    Kapoor, A.
    Kalwar, A.
    Kumar, A.
    Narayan, S.
    Lal, S.
    Beniwal, S. K.
    ANNALS OF ONCOLOGY, 2015, 26 : 138 - 138
  • [32] MAINTENANCE PEMETREXED (PEM) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC AFTER PEM PLUS CISPLATIN FOR ADVANCED NONSQUAMOUS NSCLC
    Obasaju, C. K.
    Paz-Ares, L. G.
    De Marinis, F.
    Dediu, M.
    Thomas, M.
    Pujol, J. L.
    Bidoli, P.
    Molinier, O.
    Sahoo, T. P.
    Laack, E.
    Reck, M.
    Corral, J.
    Melemed, S. A.
    John, W. J.
    Chouaki, N.
    Zimmermann, A.
    Visseren-Grul, C. M.
    Gridelli, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 8 - 8
  • [33] A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
    Qin, Shukui
    Fang, Weijia
    Ren, Zhenggang
    Ou, Shuangyan
    Lim, Ho Yeong
    Zhang, Feng
    Lee, Kin Chung
    Choi, Hye Jin
    Tong, Jiandong
    Tao, Min
    Xu, Aibing
    Cheng, Ashley
    Lu, Chang-Hsien
    Chiu, Chang-Fang
    Wahid, Mohamed Ibrahim Abdul
    Kamble, Shital
    Norquist, Josephine M.
    Zhong, Wenyan
    Li, Chen
    Chen, Zhendong
    LIVER CANCER, 2024, 13 (04) : 389 - 400
  • [34] TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments.
    Ilson, David H.
    Tabernero, Josep
    Shitara, Kohei
    Winkler, Robert
    Nasermoaddeli, Ali
    Ding, Cliff
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
    Bellmunt, Joaquim
    Theodore, Christine
    Demkov, Tomasz
    Komyakov, Boris
    Sengelov, Lisa
    Daugaard, Gedske
    Caty, Armelle
    Carles, Joan
    Jagiello-Gruszfeld, Agnieszka
    Karyakin, Oleg
    Delgado, Francois-Michel
    Hurteloup, Patrick
    Morsli, Nassim
    Salhi, Yacine
    Culine, Stephane
    von der Maase, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4454 - 4461
  • [36] A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study
    Daniele, Bruno
    Di Maio, Massimo
    Gallo, Ciro
    Gasbarrini, Antonio
    Carteni, Giacomo
    Di Costanzo, Giovan Giuseppe
    Craxi, Antonio
    Cabibbo, Giuseppe
    Bolondi, Luigi
    Granito, Alessandro
    Missale, Gabriele
    Frassoldati, Antonio
    Angelico, Mario
    Roselli, Mario
    Daniele, Gennaro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt
    Elsisi, Gihan Hamdy
    Nada, Yousery
    Rashad, Noha
    Carapinha, Joao
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 163 - 168
  • [38] AERIO News in brief Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
    Cochereau, D.
    Tredaniel, J.
    ONCOLOGIE, 2013, 15 (01) : 61 - 62
  • [39] Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma (vol 10, 837854, 2022)
    Xie, Qian
    Zheng, Hanrui
    Chen, Ye
    Peng, Xingchen
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [40] Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
    Ryoo, Baek-Yeol
    Merle, Philippe
    Kulkarni, Amit S.
    Cheng, Ann-Lii
    Bouattour, Mohamed
    Lim, Ho Yeong
    Breder, Valeriy
    Edeline, Julien
    Chao, Yee
    Ogasawara, Sadahisa
    Yau, Thomas
    Garrido, Marcelo
    Chan, Stephen L.
    Daniele, Bruno
    Norquist, Josephine M.
    Chen, Erluo
    Siegel, Abby B.
    Zhu, Andrew X.
    Finn, Richard S.
    Kudo, Masatoshi
    CANCER, 2021, 127 (06) : 865 - 874
12345